Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV vs Oral Iron for IDA in Post-Bariatric Surgery
NCT04268849Phase 3Recruiting
- Sponsor
- Auerbach Hematology Oncology Associates
- Start
- Feb 2020
- Primary completion
- Nov 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ferumoxytol in iron deficiency anemia (IDA) (2 arms), sponsored by Auerbach Hematology Oncology Associates. Primary endpoints: Clinical Global Impression - Improvement at 6 weeks and Hemoglobin Concentration at 6 weeks. Started Feb 2020; status: recruiting.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT04268849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268849.